---
title: "Remepy secures $36m funding for hybrid drug pipeline expansion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295781659.md"
description: "Remepy secured $36 million in Series A funding, led by OG Venture Partners and M Ventures, bringing total capital to $62 million. The funds will support the global Phase III clinical trial for its lead product, Hybridopa, targeting Parkinson’s disease, commencing in Q4 2026. Remepy develops hybrid drugs combining prescription medicines with AI-driven therapeutic applications. This financing aids pipeline expansion and strategic partnerships, including a recent collaboration with Merck KGaA."
datetime: "2026-08-13T09:06:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295781659.md)
  - [en](https://longbridge.com/en/news/295781659.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295781659.md)
generator: "portal-rs"
---

# Remepy secures $36m funding for hybrid drug pipeline expansion

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [MKKGY.US](https://longbridge.com/en/quote/MKKGY.US.md)

## Related News & Research

- [Security Risk Advisors Launches SCALR AI as a Free SOC AI Platform for Security Teams](https://longbridge.com/en/news/297523531.md)
- [Former Miami Mayor Francis Suarez Joins HelloGov AI as Advisor to the Board](https://longbridge.com/en/news/297064972.md)
- [Lyken.AI Announces Non-Binding MOU for 128-Node B300 AI Compute Cluster | GPUSF Stock News](https://longbridge.com/en/news/296907892.md)
- [00:20 ETOperata deepens Observability across AI to human agents - launching the control layer for CX](https://longbridge.com/en/news/297264127.md)
- [MoneyMasters Podcast: Rosenberg on Why the AI Boom Is RISKIER Than You Think](https://longbridge.com/en/news/297239245.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**